KFDA warns possible cardiovascular events over 56 anti-obesity drugs

Published: 2010-01-27 06:59:00

Updated: 2010-01-27 06:59:00

Over 56 drug companies marketing anti-obesity drug sibutramine under a variety of brand names are likely to soon face a ban on selling the medicine.

The Korea Food and Drug Administration will initiate steps to ascertain the safety profile of the medicine. KFDA started the probe after an exper...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK